Christopher Hite

Executive Vice President & Vice Chairman
Royalty Pharma

Christopher Hite is an EVP and Vice Chairman at Royalty Pharma. Prior to joining Royalty Pharma in 2020, Mr. Hite was an investment banker at Citi where he was the Global Head of Healthcare for nearly 12 years and most recently a Vice Chairman of Banking, Capital Markets and Advisory (“BCMA”) and sat on the Executive Committee of BCMA. Prior to joining Citi, Mr. Hite was the Global Head of Healthcare at Lehman Brothers. Mr. Hite serves on the Board of Advisors of Faster Cures, a center of the Milken Institute, and served on the Board of Directors of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for $11.5 billion. Mr. Hite has advised hundreds of healthcare companies on everything from mergers and acquisitions to capital formation through equity and debt issuances to capital structure. A few examples of M&A transactions where Hite advised include Celgene on its sale to Bristol-Myers Squibb for $90 billion, Shire on its sale to Takeda for $82 billion, GSK on its acquisition of Novartis Consumer for $13 billion, GSK in its JV with Pfizer to form Haleon Consumer Healthcare, Gilead on its acquisition of Forty-Seven, Inc. for $4.9 billion and Roche on several acquisitions, most recently its acquisition of Spark Therapeutics for $4.8 billion. Mr. Hite has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.